Literature DB >> 7325636

Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus.

D R Moorman, G L Mandell.   

Abstract

Twenty clinical isolates of Staphylococcus aureus were examined to determine the frequency of rifampin-resistant variants. All isolates were highly susceptible to rifampin, with mean minimum inhibitory concentrations of 0.11 +/- 0.1 microgram/ml and mean minimum bactericidal concentrations of 0.22 +/- 0.2 microgram/ml. The frequency of isolation of resistant variants was similar to all rifampin concentrations tested. Rifampin-resistant variants maintained their resistance upon daily subculture in rifampin-free broth. Rifampin-susceptible S. aureus exhibited a growth and survival advantage over the rifampin-resistant mutants both in pure cultures and in mixtures with rifampin-resistant antecedents. A comparison of the virulence for mice of five susceptible isolates and their 100 microgram/ml-rifampin-resistant variants showed that two of the resistant variants were less virulent than the susceptible strains via intraperitoneal challenge, whereas three of the resistant variants were less virulent by intravenous challenge (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7325636      PMCID: PMC181786          DOI: 10.1128/AAC.20.6.709

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Effect of rifampin on nasal carriage of Staphylococcus aureus.

Authors:  M A Sande; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

2.  Development of drug resistance to rifampicin.

Authors:  A Manten; L J Van Wijngaarden
Journal:  Chemotherapy       Date:  1969       Impact factor: 2.544

3.  Bacteriologic studies of rifampin, a new semisynthetic antibiotic.

Authors:  C M Kunin; D Brandt; H Wood
Journal:  J Infect Dis       Date:  1969-02       Impact factor: 5.226

4.  Virulence of rifampicin-resistant mutants of Shigella and enteropathogenic Escherichia coli with special reference to their cell invasiveness.

Authors:  Y Osada; T Une; M Nakajo; H Ogawa
Journal:  Jpn J Microbiol       Date:  1973-07

5.  [Virulence of rifampicin-resistant mutants of bacteria].

Authors:  T Watanabe; K Sugawara; M Watanabe
Journal:  Nihon Saikingaku Zasshi       Date:  1971-06

Review 6.  Rifampicin, a general review.

Authors:  G Binda; E Domenichini; A Gottardi; B Orlandi; E Ortelli; B Pacini; G Fowst
Journal:  Arzneimittelforschung       Date:  1971-12

7.  Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction.

Authors:  G L Mandell
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

8.  Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

9.  The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis.

Authors:  R M Massanari; S T Donta
Journal:  Chest       Date:  1978-03       Impact factor: 9.410

10.  Treatment of experimental staphylococcal infection with rifampin.

Authors:  M C Lobo; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

View more
  16 in total

Review 1.  Antimicrobial resistance of Staphylococcus aureus: genetic basis.

Authors:  B R Lyon; R Skurray
Journal:  Microbiol Rev       Date:  1987-03

2.  Isolation of rifampin-resistant mutants of Listeria monocytogenes and their characterization by rpoB gene sequencing, temperature sensitivity for growth, and interaction with an epithelial cell line.

Authors:  R Morse; K O'Hanlon; M Virji; M D Collins
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

3.  Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease.

Authors:  P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Biological cost of rifampin resistance from the perspective of Staphylococcus aureus.

Authors:  Thomas A Wichelhaus; Boris Böddinghaus; Silke Besier; Volker Schäfer; Volker Brade; Albrecht Ludwig
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Protective properties of rifampin-resistant rough mutants of Brucella melitensis.

Authors:  R Adone; F Ciuchini; C Marianelli; M Tarantino; C Pistoia; G Marcon; P Petrucci; M Francia; G Riccardi; P Pasquali
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

6.  Genetic bases of the rifampin resistance phenotype in Brucella spp.

Authors:  Cinzia Marianelli; Franco Ciuchini; Michela Tarantino; Paolo Pasquali; Rosanna Adone
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

7.  Ultrastructural cell wall characteristics of clinical gentamycin-resistant Staphylococcus aureus isolates.

Authors:  Kenji Fukutsuji; Sakuo Yamada; Tamotsu Harada
Journal:  Med Mol Morphol       Date:  2013-01-22       Impact factor: 2.309

8.  Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

Authors:  P Van der Auwera; J Klastersky; J P Thys; F Meunier-Carpentier; J C Legrand
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

9.  Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Authors:  Aashish Srivastava; David Degen; Yon W Ebright; Richard H Ebright
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 10.  Treatment of severe infections caused by penicillin-resistant pneumococci. Role of third generation cephalosporins.

Authors:  E Rubinstein; B Rubinovitch
Journal:  Infection       Date:  1994       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.